Sobi gets a long-lasting grip on a rare type of Hemophilia

19/08/2015 - 3 minutes

In the 19th century, Queen Victoria passed the Hemophilia B to diverse royal houses of Europe. Today, its characteristic heavy bleedings can be treated quite well, as Swedish Orphan Biovitrum (Sobi) and its partner Biogen showed in the results of an ongoing long-term study.

Sobi was formed in 2001 through a fusion of several units of today’s Pfizer. Dedicated to treating rare diseases, it mostly lives from sales revenues and the manufacturing of Pfizer’s hemophilia treatment. Sobi can actually handle the disease quite well with its proper treatment Alprolix.

Hemophilia B, or Christmas disease, is a genetic disease caused by a mutation in the factor IX gene. Since it’s located on the X chromosome, the disease affects mostly males (males have just one X chromosome, so one mutation means they get the disease) as we know it from the history of European royalty. The corresponding protein, factor IX, is needed for normal blood clotting. In approximately 28,500 patients worldwide, this protein has reduced or no activity,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!